Loading...
Loading...
AMAM| Name | Value |
|---|---|
| Revenues | 2,245.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 2,245.0K |
| Operating Expense | -15,943.5K |
| Operating I/L | -8,669.0K |
| Other Income/Expense | -4,474.0K |
| Interest Income | 555.5K |
| Pretax | -13,143.0K |
| Income Tax Expense | 110.5K |
| Net Income/Loss | -13,253.5K |
Ambrx Biopharma Inc. is a clinical-stage biologics company specializing in engineered precision biologics using its proprietary expanded genetic code technology platform. The company's lead product candidate, ARX788, is an anti-HER2 antibody-drug conjugate (ADC) being investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors. Additionally, Ambrx is developing two earlier-stage product candidates, ARX517 and ARX305, as well as multiple product candidates targeting immuno-oncology applications, including ARX822 and ARX102. The company generates revenue through collaborations with pharmaceutical and biotech companies for the development and commercialization of its product candidates.
